Affiliation: | 1. Pharmaceutical Chemistry Department, Faculty of Pharmacy, Deraya University, New Minia, Egypt;2. Pharmaceutical Chemistry Department, Faculty of Pharmacy, Deraya University, New Minia, Egypt Contribution: Conceptualization, Investigation, Supervision;3. Faculty of Pharmacy, Deraya University, New Minia, Egypt Contribution: Conceptualization;4. Faculty of Pharmacy, Deraya University, New Minia, Egypt Contribution: Investigation |
Abstract: | Darolutamide is an oral nonsteroidal androgen receptor antagonist used to delay the process of prostate cancer to metastatic disease and to increase the quality of life for people with advanced prostate cancer. Here, a second spectrofluorimetric method was advanced for quantifying Darolutamide in pharmaceutical formulation and spiked human plasma. This method depends on the fluorescence derivatization of Darolutamide with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole (NBD-Cl) at 75°C in a (pH 9) of borate buffer to produce a fluorescent derivative that can be detected at 520 nm after excitation at 460 nm. The method has been validated using ICH criteria, and it demonstrated linearity in the range 5–200 ng ml−1. The limit of detection (LOD) and limit of quantitation (LOQ) were 1.15 and 3.84 nm, respectively. The proposed method was applied precisely and accurately for quantifying Darolutamide within the pharmaceutical formulation and spiking human plasma without any interferences. Moreover, the method's sustainability was evaluated and compared with the published method using two greenness assessment tools termed analytical eco-scale and Analytical GREEnness (AGREE). These findings suggest that the method is more sustainable than the published method. |